Atezolizumab After Definitive Local Therapy Fails to Improve Survival in HNSCC
Patients with head and neck squamous cell carcinoma treated with atezolizumab after definitive local therapy did not see improvements in survival outcomes.
Patients with head and neck squamous cell carcinoma treated with atezolizumab after definitive local therapy did not see improvements in survival outcomes.
For people with no family history of colon cancer or other risk factors Swedish researchers found that screening every 15 years was still protective.
Apalutamide with androgen deprivation therapy following radical prostatectomy led to a biochemical recurrence-free survival rate of 100% after 2 years among patients with high-risk prostate…
Investigators examined survival rates following autologous and allogeneic hematopoietic cell transplantation among patients from multiple racial and ethnic groups and subsequently identified persisten…
Florida Cancer Specialists & Research Institute, LLC is calling for reform in value-based oncology care modeling.
Cretostimogene grenadenorepvec elicited durable responses in high-risk BCG-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ.
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
This Medical News story discusses new USPSTF recommendations about the timing of screening mammograms.
Caellagh Catley worked with the Department of Anesthesiology at Washington University School of Medicine in St. Louis to reduce carbon emissions produced by operating rooms.…
Sonrotoclax is a potent and selective BCL2 inhibitor that is also effective in venetoclax-resistant BCL2 mutants both in vitro and in vivo.The crystal stru
The purpose of this review is to summarize the literature on carotid artery stenosis (CAS) and ischemic stroke (IS) in head and neck cancer (HNC)…